Company intelligence / Profile preview
Alopexx, Inc.
Cambridge, Massachusetts, United Statesalopexx.com ↗
- Ownership
- Public · ALPX
- Development stage
- Phase 2
01
Overview
AV0328 vaccine has completed Phase 1 trials showing it induces protective antibodies against PNAG-expressing pathogens. F598 monoclonal antibody has completed Phase 1 and pilot Phase 2 trials with no serious adverse events, providing 2-3 months of protection after a single infusion.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Bharat BiotechBiotech Consortia Inc.
Beyond the preview
Go deeper on Alopexx, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alopexx, Inc..